Barclays Cuts Elanco Animal Health (NYSE:ELAN) Price Target to $19.00

Elanco Animal Health (NYSE:ELAN) had its target price cut by Barclays from $20.00 to $19.00 in a research report report published on Wednesday morning,Benzinga reports. They currently have an overweight rating on the stock.

Other equities analysts have also issued research reports about the stock. Morgan Stanley cut their price target on shares of Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 29th. UBS Group started coverage on shares of Elanco Animal Health in a report on Monday, December 9th. They set a “buy” rating and a $18.00 price target on the stock. Leerink Partners started coverage on shares of Elanco Animal Health in a report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price target on the stock. Leerink Partnrs upgraded shares of Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. Finally, Stifel Nicolaus cut their price target on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, February 21st. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $15.83.

Elanco Animal Health Stock Performance

NYSE ELAN opened at $11.19 on Wednesday. The firm’s fifty day moving average price is $11.71 and its two-hundred day moving average price is $13.03. The stock has a market cap of $5.53 billion, a PE ratio of 27.96, a PEG ratio of 2.50 and a beta of 1.42. Elanco Animal Health has a fifty-two week low of $10.20 and a fifty-two week high of $18.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business’s quarterly revenue was down 1.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.08 EPS. On average, equities analysts expect that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Hedge Funds Weigh In On Elanco Animal Health

Several hedge funds and other institutional investors have recently bought and sold shares of ELAN. CoreCap Advisors LLC acquired a new position in shares of Elanco Animal Health during the fourth quarter valued at about $29,000. AM Squared Ltd acquired a new position in shares of Elanco Animal Health during the third quarter valued at about $34,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Elanco Animal Health during the third quarter valued at about $35,000. Farther Finance Advisors LLC raised its holdings in shares of Elanco Animal Health by 158.7% during the third quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock valued at $49,000 after purchasing an additional 2,044 shares during the period. Finally, Venturi Wealth Management LLC raised its holdings in shares of Elanco Animal Health by 89.9% during the third quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock valued at $50,000 after purchasing an additional 1,601 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.